The antibacterial activity of LY164846, a new orally administered semisynthetic cephalosporin, was compared with that of amoxicillin-clavulanic acid against 492 potentially pathogenic respiratory tract and dermal isolates. Against groups A, B, and G streptococci; pneumococci; staphylococci (other than methicillin resistant); Haemophilus influenzae; BranhameUa catarrhalis; and meningococci, the MICs for 90% of strains tested of LY164846 and amoxicillin-clavulanic acid were s4 and .1 ,ug/ml, respectively. LY164846 was equally active against ,3-lactamase-positive and - 
LY164846 {7-[D(aminobenzo(b)thien-3-ylacetyl)amino]-3-
methyl-3-cephem-4-carboxylic acid} is a semisynthetic, orally administered cephalosporin that is structurally similar to cephalexin but that differs from cephalexin in that it is relatively P-lactamase stable and lacks activity against members of the family Enterobacteriaceae. LY164846 has activity against a variety of respiratory and dermal bacterial pathogens, including facultatively anaerobic and anaerobic cocci, Haemophilus sp., and Branhamella catarrhalis (D. Against two strains each of 1-lactamase-negative and -positive strains of H. influenzae, MBCs of LY164846 and amoxicillin-clavulanic acid ranged from 0.5 to 2 and from 8 CFU/ml for inoculum studies. Actual colony counts were performed in each case. Tubes containing twofold dilutions of antibiotic solutions were inoculated beneath the surface. Without shaking, tubes were incubated at 35°C for 20 h, at which time they were vortexed and reincubated. Tubes were vortexed at 24 h, and 0.1 ml from tubes showing no growth was subcultured onto brain heart infusion agar or chocolate blood agar. For tests with inocula of 106 CFU/ml, 0.01 ml was also subcultured in duplicate. Subcultures were incubated at 35°C for 48 h before colonies were counted. The MBC was defined as the lowest drug concentration showing .99.9% killing. For pH studies, broth media were adjusted to pHs 6.4, 7.4, and 8.4. For serum studies, pooled human serum was added to broth media to yield concentrations of 10 and 50%.
Time-kill studies were performed as described above for the broth macrodilution tests. Killing kinetics of LY164846 were compared with those of amoxicillin-clavulanic acid against H. influenzae and with cephalexin against S. aureus.
Drugs were tested at concentrations of one, two, and four times the MICs. Five tubes of each concentration were inoculated to yield 105 CFU/ml without shaking. Tubes were vortexed immediately prior to sampling at 0, 2, 4, and 8 h and were discarded after each sampling time. The last set of tubes was vortexed at 20 h and again immediately prior to MBCs of LY164846 and cephalexin against P-lactamasenegative and -positive strains of S. aureus were difficult to interpret because of skipped tubes or paradoxic effect. One Varying the inoculum size of H. influenzae or S. aureus from 104 to 106 CFU/ml had little or no effect on the activity of LY164846. Likewise, the activity of LY164846 was minimally affected by varying the pH from 6.4 to 8.4 or by adding 10 or 50% human serum. The growth of one H. influenzae strain was inhibited by 50% human serum alone.
Time-kill curves demonstrated a substantial amount of strain variation (Figures 1 through 4) . At concentrations of four times the MIC, H. influenzae 16 (Fig. 1) showed a 3 .5 or 2.5 log10 decrease in CFU/ml with either LY164846 or amoxicillin-clavulanic acid by 8 h, whereas strain 9 (Fig. 2) showed only a 1.0 or 1.5 log10 decrease with either drug at four times the MIC in 8 h. Similarly, by 8 h, S. aureus ATCC 29213 (Fig. 3) had a 1 .0 or 1.5 log10 decrease in CFU/ml with either LY164846 or cephalexin, whereas S. aureus 3 (Fig. 4) had a 2.0 or 3.5 log10 decrease in CFU/ml with LY164846 or cephalexin, respectively. There was no consistent difference in killing rates between LY164846 and either comparison drug. Regrowth was observed after 8 h for some strains at concentrations of one or two times the MICs. However, by 24 h all strains showed from 3 log10 decrease in CFU/ml to complete killing by two times the MIC of LY164846 or amoxicillin-clavulanic acid or by four times the MIC of cephalexin.
A scattergram relating zone diameters of inhibition by the 30-,ug LY164846 disk to MICs is shown in Fig. 5 . Based on an expected achievable level of 4 ,ug/ml in serum (D. A. Preston, personal communication), only 26 (35%) of the 74 isolates with MICs of >8 ,ug/ml were on scale. Thus, the error-rate-bounded, rather than the regression curve, method was adapted to analyze our data (3). Strains with MICs of c4 ,ug/ml were classified as susceptible, whereas those with MICs of >8 jig/ml were classified as resistant. An 29213 , and Streptococcus faecalis ATCC 29212 were 0.5, 1, and 64 ,ug/ml, respectively; and the corresponding zone diameters of inhibition were 29, 30, and 6 mm, respectively.
In conclusion, results of this study demonstrate that LY164846 is very active against a variety of respiratory and dermal isolates. Its potential clinical utility needs to be supported with toxicity data and clinical trials.
